Semplicini A, Pessina A C, Rossi G P, Hlede M, Morandin F
Clin Pharmacol Ther. 1983 Mar;33(3):278-82. doi: 10.1038/clpt.1983.33.
The hypotensive effect of short-term labetalol, the alpha- and beta-adrenoceptor blocker, is greater in subjects in the orthostatic position, possibly because of the alpha-adrenoceptor blockade. During prolonged use the orthostatic blood pressure fall disappears. To verify whether or not this is due to reduction in alpha-blocking activity, phenylephrine-induced increase in blood pressure was studied in six subjects with mild essential hypertension before and after 3 and 6 days and 1 and 6 mo of continuous treatment with 200 mg labetalol three times a day by mouth. At the same intervals, isoproterenol-induced tachycardia was followed to assess beta-blockade. After 3 days on labetalol, the log dose-response curve of phenylephrine-induced increase in blood pressure shifted to the right and the dose of agonist required to elicit a 20% increase in systolic pressure was 1.7 times that before treatment. There was a progressive decline in the dose of agonist that induced the same increase in pressure so that after 6 mo of continuous labetalol it was the same as control. In contrast, the amount of isoproterenol needed to induce a 20% increase in heart rate was two to three times that before labetalol and did not change throughout 6 mo of therapy. These data indicate a decline in the alpha-adrenoceptor-blocking effect of oral labetalol without concomitant change in the degree of beta-adrenoceptor blockade. This might account for the disappearance of orthostatic hypotension early in the course of treatment and for some decrease in the antihypertensive efficacy of labetalol.
α和β肾上腺素能受体阻滞剂拉贝洛尔的短期降压作用在处于直立位的受试者中更强,这可能是由于α肾上腺素能受体阻滞所致。在长期使用过程中,直立性血压下降消失。为了验证这是否是由于α阻滞活性降低所致,对6例轻度原发性高血压患者在口服200mg拉贝洛尔每日3次连续治疗3天、6天、1个月和6个月前后,研究了去氧肾上腺素引起的血压升高情况。在相同间隔时间,观察异丙肾上腺素引起的心动过速以评估β阻滞情况。服用拉贝洛尔3天后,去氧肾上腺素引起的血压升高的对数剂量反应曲线右移,使收缩压升高20%所需的激动剂剂量是治疗前的1.7倍。引起相同血压升高的激动剂剂量逐渐下降,以至于连续服用拉贝洛尔6个月后与对照相同。相反,使心率升高20%所需的异丙肾上腺素量是服用拉贝洛尔前的2至3倍,并且在整个6个月的治疗过程中没有变化。这些数据表明口服拉贝洛尔的α肾上腺素能受体阻滞作用下降,而β肾上腺素能受体阻滞程度没有相应改变。这可能解释了治疗早期直立性低血压的消失以及拉贝洛尔降压疗效的一些降低。